Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

While often seen as a gift, high intelligence can come with its own unique set of challenges, particularly when navigating a ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Mphasis, (BSE: 526299; NSE: MPHASIS), an Information Technology (IT) solutions provider specializing ...

The Food and Drug Administration has granted Fast Track designation to PMN310 for the treatment of Alzheimer disease.

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ( ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...